Sepetaprost demonstrated noninferiority to timolol 0.5% in decreasing intraocular pressure for patients with glaucoma or ocular hypertension.

Researchers evaluated the intraocular pressure (IOP) reduction from baseline and topical IOP-lowering medication burden following the administration of a travoprost intracameral implant. Compared with ...

and in its product candidate PAXTRAVA™ (travoprost intracameral injection or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.

The approved NDA is for iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog designed for a single administration per eye to treat glaucoma. Tandem Diabetes Care, an American ...